Identification

Name
Thiothixene
Accession Number
DB01623
Type
Small Molecule
Groups
Approved
Description

A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics. [PubChem]

Structure
Thumb
Synonyms
  • (e)-thiothixene
  • cis-thiothixene
  • Thiothixine
  • Tiotixene
  • Tiotixeno
  • Tiotixenum
External IDs
NSC-108165 / P-4657 B
Product Ingredients
IngredientUNIICASInChI Key
Thiothixene hydrochlorideB3CRJ1EWJU22189-31-7MEUAAEMCZUPORO-LRSHZYOCSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Navane Cap 2mgCapsule2 mgOralErfa Canada 2012 Inc1969-12-312015-06-05Canada
Navane Cap 5mgCapsule5 mgOralErfa Canada 2012 Inc1969-12-31Not applicableCanada
Navane Capsules 10mgCapsule10 mgOralErfa Canada 2012 Inc1969-12-312015-06-05Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ThiothixeneCapsule5 mg/1OralRemedy Repack2007-05-16Not applicableUs
ThiothixeneCapsule10 mg/1OralSandoz1987-06-24Not applicableUs
ThiothixeneCapsule10 mg/1OralRemedy Repack2011-07-192016-10-13Us
ThiothixeneCapsule10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
ThiothixeneCapsule1 mg/1OralRemedy Repack2011-10-252016-12-02Us
ThiothixeneCapsule10 mg/1OralRemedy Repack2007-04-24Not applicableUs
ThiothixeneCapsule5 mg/1OralMylan Pharmaceuticals1987-06-23Not applicableUs
ThiothixeneCapsule2 mg/1OralSandoz1987-06-24Not applicableUs
ThiothixeneCapsule5 mg/1OralMylan Institutional1998-03-05Not applicableUs
ThiothixeneCapsule5 mg/1OralCarilion Materials Management1987-06-23Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ThiothixeneCapsule1 mg/1OralRemedy Repack2017-11-09Not applicableUs
International/Other Brands
Navan / Navaron / Orbinamon
Categories
UNII
7318FJ13YJ
CAS number
3313-26-6
Weight
Average: 443.625
Monoisotopic: 443.170118567
Chemical Formula
C23H29N3O2S2
InChI Key
GFBKORZTTCHDGY-UWVJOHFNSA-N
InChI
InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
IUPAC Name
(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide
SMILES
CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1

Pharmacology

Indication

For the management of schizophrenia.

Structured Indications
Pharmacodynamics

Thiothixene is an antipsychotic of the thioxanthene series. Navane possesses certain chemical and pharmacological similarities to the piperazine phenothiazines and differences from the aliphatic group of phenothiazines. Although widely used in the treatment of schizophrenia for several decades, thiothixene is seldom used today in favor of atypical antipsychotics such as risperidone.

Mechanism of action

Thiothixene acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AD(1A) dopamine receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

10-20 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include central nervous system depression, coma, difficulty swallowing, dizziness, drowsiness, head tilted to the side, low blood pressure, muscle twitching, rigid muscles, salivation, tremors, walking disturbances, and weakness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThiothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineThiothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThiothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Thiothixene can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thiothixene.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thiothixene.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiothixene.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Amantadine.Approved
AmiodaroneThiothixene may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Thiothixene.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amperozide.Experimental
AmphetamineThiothixene may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AnagrelideThiothixene may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiothixene.Approved, Investigational
Arsenic trioxideThiothixene may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThiothixene may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Articaine.Approved
AsenapineThiothixene may increase the QTc-prolonging activities of Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Azaperone.Investigational, Vet Approved
AzelastineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThiothixene may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Barbital.Illicit
BedaquilineThiothixene may increase the QTc-prolonging activities of Bedaquiline.Approved
BenperidolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benzocaine.Approved
BenzphetamineThiothixene may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benzyl alcohol.Approved
BortezomibThe metabolism of Thiothixene can be decreased when combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Bupivacaine.Approved, Investigational
BuprenorphineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiothixene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiothixene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiothixene.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thiothixene.Approved
CaffeineThe metabolism of Thiothixene can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Thiothixene is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiothixene.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carisoprodol.Approved
CeritinibThiothixene may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiothixene.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chloroprocaine.Approved
ChloroquineThiothixene may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorphenamine.Approved
ChlorphentermineThiothixene may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThiothixene may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThiothixene may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThiothixene may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThiothixene may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThiothixene may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiothixene.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Thiothixene can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThiothixene may increase the QTc-prolonging activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiothixene.Approved, Illicit
CrizotinibThiothixene may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Thiothixene can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapoxetine.Investigational
DeferasiroxThe serum concentration of Thiothixene can be increased when it is combined with Deferasirox.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Thiothixene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thiothixene.Approved
DetomidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineThiothixene may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thiothixene.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiothixene.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Thiothixene is combined with Diethyl ether.Experimental
DiethylpropionThiothixene may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiothixene.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiothixene.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiothixene.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiothixene.Approved, Illicit
DisopyramideThiothixene may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dixyrazine.Experimental
DofetilideThiothixene may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronThiothixene may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneThiothixene may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Thiothixene can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Thiothixene is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Illicit
DronedaroneThiothixene may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thiothixene.Approved
DyclonineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Thiothixene is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thiothixene.Approved, Investigational
EliglustatThiothixene may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiothixene.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thiothixene.Approved
ErythromycinThiothixene may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThiothixene may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Thiothixene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiothixene.Approved
EthanolThiothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiothixene.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thiothixene.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fexofenadine.Approved
FlecainideThiothixene may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flunitrazepam.Approved, Illicit
FluoxetineThiothixene may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolThiothixene may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiothixene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiothixene.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Thiothixene can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Thiothixene.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiothixene.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Thiothixene is combined with Gabapentin Enacarbil.Approved
Gadobenic acidThiothixene may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Thiothixene.Approved, Illicit, Investigational
GemifloxacinThiothixene may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineThiothixene may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Glutethimide.Approved, Illicit
GoserelinThiothixene may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThiothixene may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThiothixene may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Hexobarbital.Approved
HydrocodoneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.Approved, Illicit
HydroxyamphetamineThiothixene may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
IbutilideThiothixene may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneThiothixene may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Indiplon.Investigational
Iofetamine I-123Thiothixene may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiothixene.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Thiothixene.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiothixene.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lamotrigine.Approved, Investigational
LenvatinibThiothixene may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideThiothixene may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Levodopa.Approved
LevofloxacinThiothixene may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Thiothixene.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiothixene.Approved
LidocaineThe metabolism of Thiothixene can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Thiothixene.Approved, Investigational
LisdexamfetamineThiothixene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Thiothixene.Approved
LobeglitazoneThe metabolism of Thiothixene can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lofentanil.Illicit
LopinavirThiothixene may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiothixene.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Thiothixene.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiothixene.Approved
LumefantrineThiothixene may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Thiothixene is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Thiothixene is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Melperone.Approved, Investigational
MephedroneThiothixene may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineThiothixene may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Meptazinol.Experimental
MequitazineThiothixene may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Metaxalone.Approved
MethadoneThiothixene may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThiothixene may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiothixene.Approved
MethotrimeprazineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineThiothixene may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Thiothixene.Approved, Investigational
MetyrosineThiothixene may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Thiothixene can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.Approved, Illicit
MidomafetamineThiothixene may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Thiothixene can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Thiothixene.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Thiothixene.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Investigational
MirtazapineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAThiothixene may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thiothixene.Approved
MolindoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiothixene.Approved, Investigational
MoxifloxacinThiothixene may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiothixene.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thiothixene.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thiothixene.Approved, Withdrawn
NevirapineThe metabolism of Thiothixene can be decreased when combined with Nevirapine.Approved
NilotinibThiothixene may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiothixene.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nortriptyline.Approved
OfloxacinThiothixene may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiothixene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olopatadine.Approved
OndansetronThiothixene may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Thiothixene is combined with Opium.Approved, Illicit
OrphenadrineThiothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Thiothixene is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Thiothixene can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiothixene.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Thiothixene is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiothixene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiothixene.Approved, Investigational, Vet Approved
PaliperidoneThiothixene may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThiothixene may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeThiothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thiothixene.Approved, Investigational
PazopanibThiothixene may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Penfluridol.Experimental
PentamidineThiothixene may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiothixene.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
PerazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perazine.Investigational
PerflutrenThiothixene may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiothixene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thiothixene.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thiothixene.Approved
PhenibutThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiothixene.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenoxyethanol.Approved
PhentermineThiothixene may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Phenytoin.Approved, Vet Approved
PimozideThiothixene may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.Approved
PramipexoleThiothixene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiothixene.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Prilocaine.Approved
PrimaquineThiothixene may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Primidone.Approved, Vet Approved
ProcainamideThiothixene may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thiothixene.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.Approved, Vet Approved
PromazineThiothixene may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Promethazine.Approved
PropafenoneThiothixene may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Thiothixene is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Thiothixene is combined with PSD502.Investigational
PseudoephedrineThiothixene may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Thiothixene.Approved, Illicit
QuetiapineThiothixene may increase the QTc-prolonging activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Thiothixene.Approved
QuinidineThiothixene may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThiothixene may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thiothixene.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiothixene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiothixene.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ritanserin.Investigational
RitobegronThiothixene may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thiothixene.Approved
RomifidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Romifidine.Vet Approved
RopiniroleThiothixene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ropivacaine.Approved
RotigotineThiothixene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiothixene.Approved
SaquinavirThiothixene may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiothixene.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thiothixene.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Thiothixene.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiothixene.Approved, Vet Approved
SimeprevirThe metabolism of Thiothixene can be decreased when combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
SotalolThiothixene may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.Approved, Investigational
SulfisoxazoleThiothixene may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Thiothixene.Approved, Investigational
SuvorexantThiothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thiothixene.Approved
TelavancinThiothixene may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThiothixene may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiothixene.Approved
Tenofovir disoproxilThe metabolism of Thiothixene can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TeriflunomideThe serum concentration of Thiothixene can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thiothixene.Approved
TetracaineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrodotoxin.Investigational
ThalidomideThiothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Thiothixene can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiothixene is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Thiothixene.Approved, Withdrawn
TiagabineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Thiothixene can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Topiramate.Approved
ToremifeneThiothixene may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiothixene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiothixene.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Thiothixene is combined with Valproic Acid.Approved, Investigational
VandetanibThiothixene may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Thiothixene can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Thiothixene.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Thiothixene.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Thiothixene is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiothixene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zimelidine.Withdrawn
ZiprasidoneThiothixene may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiothixene.Approved, Investigational
ZolpidemThiothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Thiothixene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Thiothixene can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThiothixene may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15560
PubChem Compound
941651
PubChem Substance
46505564
ChemSpider
819430
BindingDB
78576
ChEBI
9571
ChEMBL
CHEMBL1201
Therapeutic Targets Database
DAP000318
PharmGKB
PA451669
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Thiothixene
ATC Codes
N05AF04 — Tiotixene
AHFS Codes
  • 28:16.08.32 — Thioxanthenes

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral2 mg
CapsuleOral5 mg
CapsuleOral10 mg
CapsuleOral1 mg/1
CapsuleOral10 mg/1
CapsuleOral2 mg/1
CapsuleOral5 mg/1
Prices
Unit descriptionCostUnit
Navane 20 mg capsule3.15USD capsule
Navane 10 mg capsule1.66USD capsule
Navane 5 mg capsule1.2USD capsule
Navane 2 mg capsule0.8USD capsule
Thiothixene 10 mg capsule0.67USD capsule
Thiothixene 5 mg capsule0.47USD capsule
Thiothixene 2 mg capsule0.31USD capsule
Thiothixene 1 mg capsule0.24USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0139 mg/mLALOGPS
logP4.01ALOGPS
logP3.36ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.86 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity137.85 m3·mol-1ChemAxon
Polarizability50.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9969
Blood Brain Barrier+0.9437
Caco-2 permeable-0.6277
P-glycoprotein substrateSubstrate0.8707
P-glycoprotein inhibitor IInhibitor0.9247
P-glycoprotein inhibitor IIInhibitor0.9036
Renal organic cation transporterNon-inhibitor0.5373
CYP450 2C9 substrateNon-substrate0.7951
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5269
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5406
Ames testNon AMES toxic0.651
CarcinogenicityNon-carcinogens0.8173
BiodegradationNot ready biodegradable0.947
Rat acute toxicity2.7586 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5093
hERG inhibition (predictor II)Non-inhibitor0.7259
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0000900000-6aa6254b49096ef09aad
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0000900000-5428adb371bd4bdc7b36
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000f-8389500000-52eb8fcb0fd8490f1c66
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-007a-4191000000-781e4a9b062cbb242a0c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00ds-2290000000-0fca1120c4649dbf4f61
MS/MS Spectrum - , positiveLC-MS/MSsplash10-007c-3593200000-8fe6b44b1210ffa933d1

Taxonomy

Description
This compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiopyrans
Sub Class
1-benzothiopyrans
Direct Parent
Thioxanthenes
Alternative Parents
Diarylthioethers / N-methylpiperazines / Organosulfonamides / Benzenoids / Aminosulfonyl compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Thioxanthene / Diarylthioether / Aryl thioether / N-alkylpiperazine / N-methylpiperazine / 1,4-diazinane / Piperazine / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Shultz PJ, Sedor JR, Abboud HE: Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. [PubMed:3039860]
  2. Oades RD, Rao ML, Bender S, Sartory G, Muller BW: Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. Behav Pharmacol. 2000 Jun;11(3-4):317-30. [PubMed:11103886]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  4. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L: Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2. [PubMed:15694263]
  5. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L: Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006 Aug;27(8):966-70. [PubMed:16867246]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Shultz PJ, Sedor JR, Abboud HE: Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. [PubMed:3039860]
  2. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T: Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm (Vienna). 2000;107(3):295-302. [PubMed:10821438]
  2. Yamada J, Sugimoto Y, Horisaka K: Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull. 1995 Nov;18(11):1580-3. [PubMed:8593484]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kitamura K, Omran AA, Nagata C, Kamijima Y, Tanaka R, Takegami S, Kitade T: Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods. Chem Pharm Bull (Tokyo). 2006 Jul;54(7):972-6. [PubMed:16819214]
  2. Rukhadze MD, Bezarashvili GS, Sidamonidze NS, Tsagareli SK: Investigation of binding process of chlorpromazine to bovine serum albumin by means of passive and active experiments. Biomed Chromatogr. 2001 Oct;15(6):365-73. [PubMed:11559920]
  3. Silva D, Cortez CM, Louro SR: Quenching of the intrinsic fluorescence of bovine serum albumin by chlorpromazine and hemin. Braz J Med Biol Res. 2004 Jul;37(7):963-8. Epub 2004 Jun 22. [PubMed:15264002]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]

Drug created on August 29, 2007 14:17 / Updated on November 19, 2017 20:34